Shanghai Adrenal Disease Cohort
Shanghai Clinical Cohort - Adrenal Disease
This project enrolls adults with adrenal diseases to collect clinical, imaging, and lab data and samples to see if better tests, diagnoses, and treatments can be developed.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Shanghai Jiao Tong University School of Medicine Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT07191951 on ClinicalTrials.gov |
What this trial studies
This observational cohort will enroll adults (18–75) diagnosed with adrenal conditions such as primary aldosteronism, Cushing's syndrome, pheochromocytoma, adrenocortical carcinoma, and congenital adrenal hyperplasia. Participants will receive standard-of-care treatment (surgery, radiotherapy, and/or medications) while researchers collect hormone assays, imaging, pathology, and molecular data and track clinical outcomes over time. The study aims to address variability in hormone testing, improve localization on imaging, clarify tumor molecular features, and identify prognostic markers from integrated datasets. Results are intended to inform subtype definitions, diagnostic criteria, and more personalized prevention and treatment strategies for adrenal diseases.
Who should consider this trial
Good fit: Adults aged 18–75 with a confirmed adrenal diagnosis (e.g., aldosteronism, Cushing's syndrome, pheochromocytoma, adrenocortical carcinoma, or congenital adrenal hyperplasia) who can give informed consent and comply with study procedures.
Not a fit: People without adrenal disease, those outside the 18–75 age range, those unwilling to consent, or patients with medical or psychological conditions that preclude participation are unlikely to receive direct benefit from this cohort.
Why it matters
Potential benefit: If successful, the cohort could enable more accurate diagnoses, clearer tumor characterization, and more personalized treatment choices that improve patient outcomes.
How similar studies have performed: Prior observational and molecular studies of specific adrenal conditions have produced useful subtype and diagnostic insights, but comprehensive integrated cohorts combining clinical, imaging, and molecular data across adrenal diseases are still relatively limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * A signed and dated informed consent form * Commitment to abide by the study procedures and cooperate with the implementation of the entire study process * Patients diagnosed with adrenal diseases, including aldosteronism, Cushing's syndrome, pheochromocytoma, adrenocortical carcinoma, and congenital adrenal hyperplasia; regardless of whether they have received adrenal surgery, radiotherapy, and/or medication therapy * Aged between 18 and 75 years Exclusion Criteria: * Subjects meeting any of the following criteria will be excluded from this study: * Refuse to sign the informed consent form * Patients without adrenal diseases * Have specified diseases or conditions (physical or psychological, identified through physical examination) that warrant exclusion from the study
Where this trial is running
Shanghai
- Jiang yiran — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Yiran Jiang
- Email: jyr11662@rjh.com.cn
- Phone: 0086-021-64370045
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.